Opinion on Pharmaceuticals and Healthcare in Middle East and Africa

Published within

« | ... | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | » »|

Type Product title / description Pub Price
Expert View
Expert View

The pharmaceutical industry faces unprecedented barriers to evolution

Despite the pharmaceutical industry's evolving business model in response to growing regulatory constraints, the sector is facing unprecedented challenges caused by the economic downturn and President Obama's planned overhaul of the US healthcare system. To continue on its journey towards 'Pharma 2.0', the industry must balance the more pressing short term issues against longer term trends.

Published By Datamonitor
23 Apr 2009
Expert View
Expert View

The pharmaceutical industry: key strategies for challenging times

With declining returns from drug development pipelines and generic erosion of drug market shares, it is a very challenging time to be in the drug manufacturing business. However, with the increasing levels of M&A and licensing activity, the big players are still able to get access to novel drugs without all the draining costs of research and development.

Published By Datamonitor
21 Mar 2007
ResearchWire
ResearchWire

Therapeutic cancer vaccine market: antigen-specific therapies lead the way

Published By Datamonitor
26 Jan 2007
CommentWire
CommentWire

Top pharmaceutical and biotech companies face slowdown in sales growth over 2008-14

A Datamonitor report has identified that the leading pharmaceutical and biotech companies face a major slowdown in sales growth out to 2014, primarily a result of the imminent patent expiries facing many blockbusters and the subsequent threat from generics. Prescription sales are expected to rise at a compound annual growth rate of just 1.2% over 2008-14, compared to a historical rate of 10.5%.

Published By Datamonitor
01 Mar 2010
ResearchWire
ResearchWire

Transplantation: a growing but problematic market

Published By Datamonitor
27 Oct 2006
ResearchWire
ResearchWire

Transplantation: Astellas takes the lead

Published By Datamonitor
18 May 2006
CommentWire
CommentWire

UCB: Vimpat's efficacy in epilepsy confirmed, but other indications offer more commercial potential

New pooled data confirm Vimpat's efficacy in the adjunctive treatment of uncontrolled partial-onset seizures in adults. The drug represents a new treatment option for patients with uncontrolled epilepsy, but its inferior efficacy to Keppra is expected to limit its uptake. Nevertheless, future indication expansions in migraine and fibromyalgia may expand Vimpat's commercial potential.

Published By Datamonitor
02 Jul 2009
ResearchWire
ResearchWire

Upper GI disorders: prevalence in the seven major markets

Published By Datamonitor
10 Aug 2007
Expert View
Expert View

Vaccine market overview 2010

Five companies account for approximately 80% of total global vaccine sales: Sanofi Pasteur, Merck & Co., GlaxoSmithKline, Pfizer, and Novartis. The key reason for this oligopoly is the high barrier to entry for smaller players, which usually have limited manufacturing capacity, and may also lack the resources and the distribution networks required for vaccine development.

Published By Datamonitor
01 Dec 2010
Expert View
Expert View

Vaccines have re-emerged as growth drivers for the biopharmaceutical industry

Prior to 2000, vaccines were generally regarded as a commodity market with limited revenue opportunities. However, advances in vaccine technology, the launch of new vaccines, increased investment in research, a change of public opinion about vaccination, and more favorable legislation regarding vaccine injury compensation have contributed to their re-emergence as successful growth drivers.

Published By Datamonitor
01 Dec 2010

« | ... | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | » »|

No help is available.